Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,418,996

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 4:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Globus Medical (GMED) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?

by Zacks Equity Research

GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Indrajit Bandyopadhyay headshot

SP Platform's 88% Procedure Growth: The Next Frontier for ISRG?

by Indrajit Bandyopadhyay

Intuitive Surgical's SP platform posts 88% procedure growth in Q2, driven by a 112% surge in Korea and expanding adoption in colorectal and thoracic surgery.

Indrajit Bandyopadhyay headshot

ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?

by Indrajit Bandyopadhyay

Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.

Zacks Equity Research

Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand

by Zacks Equity Research

GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Globus Medical (GMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of +13.16% and +0.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Globus Medical (GMED), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Zacks Equity Research

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of +25.00% and +6.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?

by Indrajit Bandyopadhyay

ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.

Zacks Equity Research

GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?

by Zacks Equity Research

Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.

Indrajit Bandyopadhyay headshot

Can ISRG Maintain Robotics Edge Amid Rising Rivalry & Budget Strain?

by Indrajit Bandyopadhyay

ISRG posted strong Q1 growth, but rising rivals and tighter hospital budgets test its robotics dominance and pricing power.

Indrajit Bandyopadhyay headshot

Intuitive Surgical's da Vinci 5: Gaining Precision, Power and Potential

by Indrajit Bandyopadhyay

ISRG's da Vinci 5 is gaining momentum with key innovations like Force Feedback and strong Q1 placements boosting adoption.

Zacks Equity Research

GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls

by Zacks Equity Research

GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.

Zacks Equity Research

Globus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of -8.11% and 4.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of 25% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -61.54% and 9.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RFG

Zacks Equity Research

Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Zacks Equity Research

Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -91.67% and 0.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.